Sequoia’s Roelof Botha warns ‘chumps’ not to buy into SPVs


One of Sequoia’s most prominent investors, managing partner Roelof Botha, sees signs of another greed cycle brewing in venture capital, one where the least sophisticated investors will likely get most hurt.

He posted a warning on X on Thursday, writing, “We remain destined to repeat the mistakes of the past! SPVs are making a come-back, where the lead investor speaks for less than 10% of the capital, yet eagerly lines up the latest set of tourist chumps who think the story will end differently this time. It’s only been 3 years.” (He punctuated the post with an exploding-head emoji.)

That last cycle ended badly. In 2022, the overheated VC market of 2021 crashed. The fallout is still ongoing, with 2025 expected to be another brutal year of failed startups.

Botha is specifically warning about special purpose vehicles (SPVs) — a structure that allows a startup’s investor to sell access to a chunk of their shares to others. But the new investors are not actually buying shares in the startup; they are buying shares of the SPV, often at greatly inflated prices. That means the startup’s valuation would have to soar just for some of the SPV share owners to break even.

SPVs are becoming especially common in AI investing, where some startups are raising astronomical sums. A search of SEC filings finds at least nine SPVs tied to Anthropic since 2024 alone. The company is reportedly in talks to raise another $3.5 billion.

Figure AI’s attempt to raise $1.5 billion is also reportedly full of SPVs, per the Information. Note that neither company is in Sequoia’s portfolio.

The trend isn’t limited to just a few companies. Nearly every major multi-billion AI company has investors offering SPVs. And if a big-name VC firm firm — say, Sequoia’s archrival Andreessen Horowitz — is leading the deal, that name alone can lure in buyers.

One person involved in the secondaries markets describes SPV-laden deals like this: “They are passing the hat on all the deals that can’t find enough VC investors and the name firm puts up a tiny amount and these stupid family offices say oh, ‘Andreessen is leading it must be good,’ even though we know that these are their worst companies that can’t raise money from traditional VCs.”

Botha’s message to these would-be investors? “Don’t buy it.”

Sequoia did not immediately respond to a request for further comment.

Anterior grabs $20M from NEA to expedite health insurance approvals with AI


Anterior, a company that uses AI to expedite health insurance approval for medical procedures, has raised a $20 million Series A round at a $95 million post-money valuation led by NEA, according to two people familiar with the deal. Existing investors Sequoia, which led Anterior’s $3.2 million seed round last September, and Neo, an accelerator that helped the company launch in the summer of 2022, also participated in the Series A financing.

The round also included a host of angel investors, including Mustafa Suleyman, a DeepMind and Inflection AI co-founder who was hired by Microsoft in March to lead the tech giant’s consumer AI division.

NEA and Anterior didn’t immediately respond to a request for comment.

Anterior, formerly known as Co:helm, was co-founded by Abdel Mahmoud, a former doctor who left medicine to pursue a master’s degree in computer science and a career in tech after he grew frustrated with the amount of time he spent on administrative functions rather than with patience.   

The company has built an LLM-powered co-pilot that helps nurses and doctors save hours on gathering medical documentation required by insurance. Anterior’s solution aims to reduce denial rates and accelerate patient access to care.

While Anterior’s initial offering is in prior authorization automation, the company eventually plans to expand into other medical administrative functions.

Mohamad Makhzoumi, managing general partner on NEA’s healthcare team and co-CEO of the firm, joined Anterior’s board. Makhzoumi’s investments include Tempus, a genomic testing and data analysis company founded by Groupon founder Eric Lefkofsky, which is planning to IPO next week at a valuation of up to $6.1 billion. Makhzoimi also backed Xaira, an AI drug discovery startup that launched this year with $1 billion in funding.

Anterior competes with Cohere Health, another provider of prior authorization automation, which raised a $50 million round in February led by Deerfield Management, with participation from Define Ventures, Flare Capital Partners, Longitude Capital and Polaris Partners, bringing the five-year-old company’s total funding to $106 million.